Citi downgraded AbbVie (ABBV) to Neutral from Buy with a price target of $205, down from $210. While the company’s current fundamentals are solid, the share impact from quarterly surprises could diminish going forward, especially as investors increasingly shift more focus to AbbVie’s pipeline, the analyst tells investors in a research note. Citi cites the company’s “comparatively lighter late-stage” pipeline versus its biopharma peers and a higher perceived policy risk than peers for the downgrade. Both of these add risk to AbbVie’s “relative safety positioning,” contends the firm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie Hold Rating: Balancing Growth in Immunology and Neuroscience Amidst Humira Challenges and Macroeconomic Uncertainties
- AbbVie Expands Board, Appoints New Independent Director
- Johnson & Johnson Stock (JNJ) Fails to Clean Up Despite Success in Near $1B Psoriasis Pill Trial
- LLY, VRTX, or ABBV: Which Healthcare Stock Is the Best Pick?
- Berenberg says pharma ’emerging from the pill penalty box’